参考文献/References:
[1] Visse R,Nagase H.Matrix metalloproteinases and tissue inhibitors of metalloproteinases[J].Circ Res,2003,92(8):827-839.
[2] Raffetto JD,Barros YV,Wells AK.MMP-2 induced vein relaxation via inhibition [Ca2+]e-Dependent mechanisms of venous smooth muscle contraction. role of RGD peptides[J].Journal of Surgical Research,2010,159(2):755-764.
[3] Ning Cui,Min Hu,Raouf AK.Biochemical and biological attributes of matrix metalloproteinases[J].Prog Mol Biol Transl Sci,2017,147:1-73.
[4] Massova I,Lakshmi PK,Fridman R,et al.Matrix metalloproteinases:structures,evolution,and Diversifification[J].FASEB J,1998,12(12):1075-1095.
[5] Murphy G,Nguyen Q,Cockett M,et al.Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant[J].J Biol Chem,1994,269(9):6632-6636.
[6] Sato H,Kinoshita T,Takino T,et al.Activation of a recombinant membrane type 1-matrix metalloproteinase(MT1-MMP)by furin and its interaction with tissue inhibitor of metalloproteinases(TIMP)-2[J].FEBS Lett,1996,393(1):101-104.
[7] Santavicca M,Noel A,Angliker H,et al.Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases[J].Biochem J,1996,315(Pt 3):953-958.
[8] Kucukguven A,Khalil RA.Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins[J].Curr Drug Targets,2013,14(3):287-324.
[9] Pei D,Kang T,Qi H.Cysteine array matrix metalloproteinase(CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation[J].J Biol Chem,2000,275(43):33988-33997.
[10] Mitchell PG,Magna HA,Reeves LM,et al.Cloning,expression,and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage[J].J Clin Invest,1996,97(3):761-768.
[11] Lu PF,Takai K,Weaver VM,et al.Extracellular matrix degradation and remodeling in development and disease[J].Cold Spring Harb Perspect Biol,2011,3(12):a005058.
[12] Nissinen L,Kähäri VM.Matrix metalloproteinases in inflammation[J].Biochim Biophys Acta,2014,1840(8):2571-2580.
[13] Mancini A,Di Battista JA.Transcriptional regulation of matrix metalloprotease gene expression in health and disease[J].Front Biosci,2006,11(11):423-446.
[14] Lee RT,Schoen FJ,Loree HM,et al.Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis[J].Implications for plaque rupture.Arterioscler Thromb Vasc Biol,1996,16(8):1070-1073.
[15] Tanindi A,Sahinarslan A,Elbeg S,et al.Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors,clinical presentation,extent and severity of atherosclerotic coronary artery disease[J].Open Cardiovasc Med J,2011,5:110-116.
[16] Kondapalli MS,Galimudi RK,Gundapaneni KK,et al.MMP 1 circulating levels and promoter polymorphism in risk prediction of coronary artery disease in asymptomatic first degree relatives[J].Gene,2016,595(1):115-120.
[17] Hu W,Wei R,Wang LY,et al.Correlations of MMP-1, MMP-3, and MMP-12 with the degree of atherosclerosis, plaque stability and cardiovascular and cerebrovascular events[J].Exp Ther Med,2018,15(2):1994-1998.
[18] Laxton RC,Hu YH,Duchene J,et al.A role of matrix metalloproteinase-8 in atherosclerosis[J].Circ Res,2009,105(9):921-U231.
[19] Okada Y,Nakanishi I.Activation of matrix metalloproteinase 3(stromelysin)and matrix metalloproteinase 2('gelatinase')by human neutrophil elastase and cathepsin G[J].FEBS Lett,1989,249(2):353-356.
[20] Naruko T,Ueda M,Haze K,et al.Neutrophil infiltration of culprit lesions in acute coronary syndromes[J].Circulation,2002,106(23):2894-2900.
[21] Kato R,Momiyama Y,Ohmori R,et al.Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease[J].Circulation Journal,2005,69(9):1035-1040.
[22] Momiyama Y,Ohmori R,Tanaka N,et al.High plasma levels of matrix metalloproteinase-8 in patients with unstable angina[J].Atherosclerosis,2010,209(1):206-210.
[23] Tuomainen AM,Nyyssönen K,Laukkanen JA,et al.Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men[J].Arterioscler Thromb Vasc Biol,2007,27(12):2722-2728.
[24] Sluijter JP,Pulskens WP,Schoneveld AH,et al.Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions-A study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms[J].Stroke,2006,37(1):235-239.
[25] Palm F,Pussinen PJ,Safer A,et al.Serum matrix metalloproteinase-8,tissue inhibitor of metalloproteinase and myeloperoxidase in ischemic stroke[J].Atherosclerosis,2018,271:9-14.
[26] Lenglet S,Mach F,Montecucco F.Role of matrix metalloproteinase-8 in atherosclerosis[Z],2013:659282.
[27] Deguchi JO,Aikawa E,Libby P,et al.Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques[J].Circulation,2005,112(17):2708-2715.
[28] Cuadrado E,Rosell A,Borrell-Pages MA,et al.Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia[J].Journal of Cerebral Blood Flow and Metabolism,2009,29(2):398-410.
[29] Ma F,Martínez-San Segundo P,Barceló V,etal.Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice[J].Neurobiol Dis,2016,91:236-246.
[30] Wagsater D,Zhu CY,Bjorkegren J,et al.MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the LdlrApob100/100 moused[J].Int J Mol Med,2011,28(2):247-253.
[31] Guo ZY,Zhang B,Yan YH,et al.Specific matrix metalloproteinases and calcification factors are associated with the vulnerability of human carotid plaque[J].Exp Ther Med,2018,16(3):2071-2079.
[32] Tanana OS,Sukmanova IA,Ponomarenko IV.The clinical significance of copeptin and matrix metalloproteinases in men with acute coronary syndrome[J].Kardiologiia,2017,57(S3):32-39.
[33] Sun H,Zhang J,Zheng Y,et al.Expressions and clinical significance of factors related to acute coronary syndrome[J].J Biol Regul Homeost Agents,2018,32(2):299-305.
[34] Jeon SB,Chun S,Choi-Kwon S,et al.Biomarkers and location of atherosclerosis: Matrix metalloproteinase-2 May be related to intracranial atherosclerosis[J].Atherosclerosis,2012,223(2):442-447.
[35] Chen LL,Yang QH,Ding R,et al.Carotid thickness and atherosclerotic plaque stability, serum inflammation, serum MMP-2 and MMP-9 were associated with acute cerebral infarction[J].Exp Ther Med,2018,16(6):5253-5257.
[36] Gough PJ,Gomez IG,Wille PT,et al.Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice[J].Journal of Clinical Investigation,2006,116(1):59-69.
[37] Volkov AM,Murashov IS,Polonskaya VY,et al.Changes of content of matrix metalloproteinases and their tissue expression in various types of atherosclerotic plaques[J].Kardiologiya,2018,58(10):12-18.
[38] Hamed GM,Fattah MF.Clinical relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome[J].Clin Appl Thromb Hemost,2015,21(8):705-711.
[39] Lahdentausta L,Leskelä J,Winkelmann A,et al.Serum MMP-9 diagnostics, prognostics, and activation in acute coronary syndrome and its recurrence[J].J Cardiovasc Transl Res,2018,11(3):210-220.
[40] Yuan RZ,Tan S,Wang D,et al.Predictive value of plasma matrix metalloproteinase-9 concentrations for spontaneous haemorrhagic transformation in patients with acute ischaemic stroke: A cohort study in Chinese patients[J].Journal of Clinical Neuroscience,2018,58:108-112.
[41] Zhong C,Yang J,Xu T,et al.Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke[J].Neurology,2017,89(8):805-812.
[42] Johnson JL,George SJ,Newby AC,et al.Divergent effects of matrix metalloproteinases 3,7,9,and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries[J].Proc Natl Acad Sci U S A,2005,102(43):15575-15580.
[43] Samnegård A,Silveira A,Tornvall P,et al.Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction[J].J Intern Med,2006,259(5):530-536.
[44] Guizani I,Zidi W,Zayani Y,et al.Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease:a 5 years cohort study[J],Mol Biol Rep,2019,46(5):4699-4707.
[45] Hafez S,Abdelsaid M,El-Shafey S,et al.Matrix metalloprotease 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke[J].Stroke,2016,47(3):843-851.
[46] Lien LM,Hsieh YC,Bai CH,et al.Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan[J].Atherosclerosis,2010,212(2):595-600.
[47] Yamada S,Wang KY,Tanimoto A,et al.Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits[J].Am J Pathol,2008,172(5):1419-1429.
[48] Jguirim-Souissi I,Jelassi A,Addad F,et al.Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease[J].American Journal of Cardiology,2007,100(1):23-27.
[49] Chelluboina B,Klopfenstein JD,Pinson DM,et al.Matrix metalloproteinase-12 induces Blood-Brain barrier damage after focal cerebral ischemia[J].Stroke,2015,46(12):3523-3531.
[50] Chelluboina B,Warhekar A,Dillard M,et al.Post-transcriptional inactivation of matrix metalloproteinase-12 after focal cerebral ischemia attenuates brain damage[Z],2015:9504.